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Squamous Cell Carcinoma
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Abstract
Tumor angiogenesis and tumor progression to late oral squamous cell carcinoma 
are closely related. Vascular endothelial growth factor (VEGF), a heparin-binding 
growth factor with mitogenic activity specific for vascular endothelial cells, 
regulates key events of the pathological angiogenesis involved in the metabolic 
functions of malignant tissues. The level of high-affinity tyrosine kinase receptor 
for VEGF, flt, in tumor endothelial cells in vivo is seen upregulated, supporting the 
role of VEGF as a potential signaling tumor angiogenesis axis in vivo and sustaining 
the notion that paracrine mechanisms are responsible for the regulation of tumor 
angiogenesis. The expression of VEGFs is increased in the processes of oral squa-
mous cell carcinoma (OSCC) progression and proliferation. Vascular endothelial 
growth factor C (VEGF-C)/VEGF3 expression induced by chemokine CCL4 is con-
nected to lymph node metastasis in OSCC. This chapter was aimed to summarize 
and analyze the findings on the role of vascular endothelial growth factor in oral 
squamous cell carcinoma and briefly discuss the potential of vascular endothelial 
growth factor that targets this pathway as treatment for OSCC.
Keywords: angiogenesis, vascular endothelial growth factor, oral cancer, 
overexpression, VEGF polymorphism
1. Introduction
The angiogenesis process involves approximately twenty factors, such as basic 
fibroblast growth factor, placenta growth factor (PIGF-1), epidermal growth factor 
(EP), as platelet-derived GF (PDGF), and the most important angiogenic factor: 
vascular endothelial growth factor (VEGF). Studies of restricted expression pat-
terns and functional roles have implicated VEGFs in the generation of new blood 
vessels from pre-existing vasculature complex genetic pathways. VEGF has since 
been documented as being a potent stimulator of endothelial cells proliferation 
and migration and to induce the expression of interstitial collagenases. Specifically, 
VEGFs regulate physiological angiogenesis, including the vessel and the organ 
development, the lymphogenesis, and the differentiation during embryogenesis, 
as well the pathogenesis of a multiplicity of disorders. The hypothesis that VEGF 
action is required for tumor angiogenesis has been first provided by the findings 
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of the vascular development of tumor xenografts in mice. These results were 
confirmed through in situ hybridization studies, showing a correlation between 
the degree of defective angiogenesis and VEGF mRNA upregulation. These studies 
uniformly concur that VEGF expression enhances tumor growth. In this chapter, we 
provide a brief historical overview of the discovery of VEGF, structural character-
ization of the other members of VEGF family and their receptor, and to summarize 
the main features of the role of vascular endothelial growth factor in angiogenesis 
of oral cancer development.
2. Discovery of VEGF
VEGF was first described in 1983 as a factor secreted by hepatocarcinoma cell 
lines [1] that increased microvascular permeability to plasma proteins in the skin 
of guinea-pigs. It was highly purified to homogeneity from pituitary folliculostel-
late cells and characterized in 1989 [2]. Other authors supported evidence that this 
protein potently stimulated endothelial cell migration [3–5]. It was named “vascular 
permeability factor” or VPF, potent inducers of vascular hyperpermeability (espe-
cially venular endothelium) to fibrinogen and other plasma proteins [6], which 
upon secretion by tumor cells, promotes vascular leakage [7]. More years later, it 
was demonstrated that VPF has potent mitogenic activity in a diversity of cell types, 
and also versus endothelial cells [8]. Vascular endothelial growth factors (VEGFs) 
are predominantly produced by endothelial, hematopoietic, and stromal cells in 
response to hypoxia and upon stimulation by growth factors such as transforming 
growth factor β (TGFβ), interleukins, or platelet-derived growth factors (PDGFs). 
VEGFs specifically interact with one or several receptor tyrosine kinases (RTKs), 
VEGF receptor −1, −2, and −3 (VEGFR-1, −2, −3), and with distinct coreceptors 
such as neuropilins or heparan sulfate glycosaminoglycans. VEGF receptors are 
classified as type V RTKs whose extracellular domains consist of seven immuno-
globulin-like (Ig-like) domains [9, 10]. The intracellular domain consists of seven 
immunoglobulin-like domains (I–VII), a single transmembrane (TM) region, and 
a tyrosine kinase consensus sequence (TK) interrupted by a cytoplasmatic kinase 
domain [11, 12].
3. The VEGF gene and isoforms
The VEGFs term identifies a large and heterogeneous family of secreted poly-
peptides, named VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta 
growth factor (PGF), characterized by a highly conserved receptor-binding 
cystine-knot structure similar to that of the platelet-derived growth factors [13, 14]. 
Of those six members, VEGF-A plays a key role in vasculogenesis and angiogen-
esis [15]. PGF is mainly expressed in placenta, heart and lungs; it is a ligand for 
VEGFR-2 and it is involved in angiogenesis regulation. VEGF-B binds VEGFR-1 
and neuropilin-1, mostly expressed in the extracellular matrix and abundantly 
expressed in brown fat, in the myocardium and skeletal muscle; it is implicated in 
high cellular energy metabolism. VEGF-C is produced as a precursor protein [16, 
17]. VEGF-C promotes mitogenesis, migration and survival of ECs [18], and regu-
lates the lymphatic vessel growth by binding to VEGF-receptor-3 (VEGFR-3, Flt-4) 
[19, 20]. VEGF-D, binds and activates VEGFR-2 and VEGFR-3, because is mito-
genic for EC, angiogenic, and lymphangiogenic. Its expression was demonstrated 
mainly in the lung and skin during embryogenesis. VEGF-E expression, binding 
the VEGFR-2, promotes the release of tissue factors, proliferation, chemotaxis and 
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sprouting of cultured vascular ECs in vitro and angiogenesis in vivo [6, 21]. The 
major function of VEGF-C consist in regulation VEGF exerts its effect on tissues at 
several levels; mechanisms range from a plethora of physiological processes which 
regulate blood vessel growth, such as during pregnancy and in tissue repair to 
pathological conditions, including chronic inflammation, would healing process, 
and cancer [6, 22]. It has been proven that VEGF causes a pronounced angiogenic 
response in a variety of in vivo models, including the chick chorioallantoic mem-
brane [23, 24]. Native VEGF is a basic, heparin-binding, homodimeric glycoprotein 
of 45,000 daltons. Interestingly, the VEGF gene has been mapped to chromosome 
6 at position p21.3 [25] and consists of eight exons and seven introns in the coding 
sequence, which covers a region of 14 kilobases. Among these, there is evidence that 
the −634G/C, −1154G/A, and −2578C/A VEGF polymorphisms have been shown to 
be associated with increased VEGF production. Alternative splicing of the mRNA 
from the gene of VEGF, VEGF-B, and PIGF results in the expression of five known 
human isoforms with differential diffusibility and heparin-binding properties con-
taining 121, 145, 165, 183, 189 and 206 amino acids with different biological proper-
ties: VEGF121, VEGF165, VEGF189, and VEGF206 [26]. The VEGF121 is a weakly acidic 
polypeptide with a 44 amino-acid insertion encoded by exon 7a, that fails to bind 
to heparin [27]; VEGF189 has a further insertion of 24 amino acids, highly enriched 
in basic residues encoded by exon 6a. VEGF121 and VEGF165 have been detected 
predominantly in normal tissue, but VEGF121 isoform is both more angiogenic and 
tumorigenic than being the 165 and 189 isoforms [27, 28]. In particular, the isoform 
121 has been shown to predominate in primary human breast carcinomas (Relf M) 
VEGF189 expression has been shown to be dominant in normal lung [29] and the 
183 isoform predominates in heart [30, 31]. Several studies have reported that the 
expression of VEGF206 occurs mainly in fetal liver.
3.1 Biological effects of VEGF expression
The VEGF and the “fibroblastic growth factor” (bFGF) demonstrate a power-
ful synergism in the promotion of angiogenesis in vitro, as shown by models using 
microvascular endothelial cells invading the three-dimensional collagen gel system 
[32, 33]. Also, VEGF exerts its effect by coordinating of angiopoietins, another 
class of angiogenic factors. Specifically, VEGF is involved in the early sequences of 
events leading to the vessel development, whereas angiopoietin 1 (Ang1), an agonist 
ligand for the endothelial-specific Tie2 receptor, binds and activates Tie2 to promote 
vessel maturation, vascular stability and leakiness [34]; Ang2 acts as a Tie2 agonist 
in lymphatic endothelial cells generating an important vascular signaling pathway 
involved in angiogenesis, vascular stability and quiescence. VEGF achieves its 
functions of endothelial cell differentiation and proliferation by binding a family of 
tyrosine kinases receptors (VEGFRs), known as Flt-1 receptor (VEGF receptor-1) 
and VEGF receptor-2 (VEGF-2 or KDR/Flk-1). VEGFR-1 binds VEGF, VEGF-B 
and PlGF with high affinity and induces weak mitogenic signals in ECs. [23, 35] 
VEGFR-1 expression is up-regulated by hypoxia via (transcription hypoxia induc-
ible factor) HIF-dependent mechanism [36, 37]. In the lung, VEGFR-1 provokes 
secretion of Matrix Metalloproteinase 9 (MMP9) at the vascular bed, thus empow-
ering metastasis. Also, it has been discovered the role of VEGFR-1 in releasing tissue 
specific factors in a perivascular specific pattern at the level of vascular endothelium 
[38]. VEGFR-2, the major mediator of endothelial cell mitogenesis, proliferation 
and survival [39, 40] binds VEGF, VEGF-C, VEGF-D, VEGF-E and PlGF [22, 39]. 
VEGFR-2 expression is down-regulated in the adult blood vascular ECs, and is 
again up-regulated in the endothelium of angiogenic process. VEGF, VEGF-C and 
VEGF-D are bound VEGFR-3 and are involved in regulation of lymphangiogenesis, 
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the growth of new lymphatic vessels [41–45]. The expression of VEGFR-3 (or Flt-4) 
is relevant in lymphatic vessels [44] and in hematopoietic cells of monocytic lineage 
[6, 42], and is also expressed in a subset of capillary endothelia [19]. Studies on 
animal models showed that VEGF-C/VEGFR-3 axis plays a crucial role in cancer 
metastasis by inducing lymphangiogenesis [46–48], but further investigations 
would be necessary. Furthermore, it has been documented the link between muta-
tions in VEGFR-3 with hereditary lymphedema, an autosomal dominant disorder of 
the lymphatic system that can lead to lymphangiosarcomas [13, 49]. Neuropilins-1 
and -2 are more important in immunology and neuronal development, but they are 
also involved in angiogenesis [19, 44]. Neuropilins, bind especially class 3 semapho-
rins but the Neuropilin-1 also binds VEGF, VEGF-B and PlGF, while Neuropilin-2 
binds VEGF, VEGF-C and PlGF [50]. When is coexpressed in cells together with 
VEGFR-2, Neuropilin-1 enhances the binding of VEGF165 to VEGFR-2 and aug-
ments tumor angiogenesis in vivo [51, 52]. Nrp-2 is expressed also on lymphatic 
ECs, and mutated Nrp-2 forms induce abnormalities in the formation of small 
lymphatic vessels and lymphatic capillaries in mice [53]. In addition, some isoforms 
bind to known as non-tyrosine kinase receptors, known as neuropilins (NRPs) 
(neuropilin-1 and neuropilin-2 (22–44)). Neuropilins-1 and -2 are also involved 
in immunology and neuronal development [50, 54]. Neuropilins bind, especially 
class 3 semaphorins but the Neuropilin-1 also binds VEGF, VEGF-B and PlGF, 
while Neuropilin-2 binds VEGF, VEGF-C and PlGF [50]. Neuropilin-1 is capable 
to improve the binding of VEGF165 to VEGFR-2 and increase tumor angiogenesis 
in vivo [51, 53]. Nrp-2 is expressed also on lymphatic ECs, and it has been shown 
in vivo that mutated Nrp-2 form alters the formation of small lymphatic vessels and 
lymphatic capillaries in mice [54]. The binding results in stimulation of cell-signaling 
pathways that act to increase cell nucleus division, and contributing to angiogenesis 
through extracellular matrix dissolution, and endothelial cell movement.
4. Role of VEGF in oral squamous cell carcinoma
4.1 The role of VEGF in invasion
Angiogenesis, the formation of new blood vessels, is not only a normal physi-
ological process, but it is closely linked to both tumor growth and metastasis, 
providing the principal pathway through tumor cells exit the primary tumor site 
and enter the circulation. A multiplicity of molecular determinants is involved in 
these different mechanisms of vascular growth, and VEGFs play a significant role in 
pathological angiogenesis. In particular, the role of VEGF-A in tumor angiogenesis 
are clarified by several studies [23, 55], but the results concerning VEGF-expression 
in normal and dysplastic oral epithelium, as well as about the potential role of 
VEGF in oral squamous cell carcinoma progression shown contradictions. VEGF-A 
overexpression has been reported in most types of cancer, including oral squamous 
cell carcinoma, and it is thought to be a prognostic factor for survival. Some studies 
revealed no altered VEGF expression in the normal and mildly dysplastic oral 
epithelium, or the expression was significantly lower than neoplastic epithelium 
[16–18]. A considerable upregulation of VEGF expression during the transition 
from normal oral epithelium through dysplasia to OSCC, but no correlation was 
found between VEGF expression and the grade of dysplasia. Many research-
ers demonstrated an upregulation of VEGF expression in cancerous tissues in 
comparison to the normal oral mucosa. These results suggest that VEGF could be 
implicated in tumor progression by expanding the vascularity during the process 
of transition from the normal oral mucosa to invasive carcinoma [18, 51–56]. 
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Immunohistochemical study of VEGF expression in oral squamous cell carcinomas 
clarify the relationship between vascular endothelial growth factor (VEGF) expres-
sion and clinicopathological factors in oral squamous cell carcinoma (OSCC), 
showing that serum VEGF levels were significantly higher in oral cancer patients as 
compared to normal controls that further showed an increasing trend with clinical 
stage and lymph node involvement, suggesting that VEGF level may be a reliable 
biomarker and may be a potential target for development of chemotherapeutic 
strategies for patients with oral carcinoma.
4.2 The role of VEGF in metastasis
Lymphangiogenesis plays a vital role in tumor growth and systemic dissemina-
tion of different carcinomas [2]. Although vascular endothelial growth factor C 
(VEGF-C) is well known to be associated with lymph node metastasis in patients 
with OSCC, inducing the production of urokinase by cancer and playing a crucial 
role in the extracellular matrix remodeling and tumor cell invasion, the specific 
mechanisms of lymphangiogenesis in OSCC are largely unknown. Further, it has 
been implicated in inducing the growth of both blood and lymphatic vessels and in 
regulation of proliferation, differentiation and migration of lymphatic endothelial 
cells in many physiological and pathological conditions [19, 20]. Overexpression 
of VEGF-C has been detected in various malignancies and is frequently associated 
with lymphatic invasion, nodal and distant metastasis and consequently poor 
survival [23, 33]. VEGF-C signaling is involved in the progression of several malig-
nancies that put forward VEGF-C as a potential target for the development of new 
anticancer therapies to prevent local invasion and metastatic spread of disease. The 
progression of several malignancies involves VEGF-C signaling. The immunohisto-
chemical analysis and real-time quantitative RT-PCR studies showed a significant 
correlation between the levels of VEGF-C mRNA expression in a human OSCC cell 
line, through the phosphoinositide 3-kinase-Akt pathway. The angiogenic action 
of this growth factor is achievable by binding to two receptor tyrosine kinases 
(RTK), VEGFR-1 (Flt-1) and VEGFR-2 (KDR, Flk-1) [17, 22]. VEGFR-2 is the 
major mediator of the mitogenic, angiogenic and permeability-enhancing effects 
of VEGF-A, while the role of VEGFR-1 in the regulation of angiogenesis is con-
troversial. It is implicated in a paracrine release of growth factors, but the central 
role of this receptor is to prevent the interaction of VEGF with VEGFR-2. Also, it 
may promote angiogenesis by recruitment in tumor vasculature of monocytes and 
other bone marrow-derived cells [48, 52, 57]. Moreover, VEGFR-1 is involved in the 
induction of matrix metalloproteinases [49] that retrovirus-mediated expression of 
a dominant negative VEGFR-2, because of inhibition of signal transduction through 
wild-type VEGFR-2, suppression of the growth of glioblastoma multiforme and 
other tumor cell lines in vivo. Correlation of VEGF expression with clinical stage 
of OSCC is controversial. Clinicopathologic findings suggest that evaluation of 
VEGF expression is of prognostic value in patients with OSCC. VEGF expression 
was found to increase significantly with advancing stage of the tumor. Elevated 
expression of VEGF was associated with aggressive phenotype and advanced stage 
of the tumor [58], as well as demonstrated by Yu Hong Li et al. which found a 
higher VEGF expression in stage 3 and 4 tumors as compared to stage 1 and 2 [59]. 
An explanation could be attributed to the correlation with the intensity of VEGF 
expression and the degree of differentiation or invasiveness of carcinoma. The 
results support the findings of previous results on the average density of immuno-
histochemistry (IHC), indicating that in normal oral squamous cells, VEGF expres-
sion was detected only in the vascular endothelial cells in the mesenchymal tissues 
[60, 61]. According to these results, to Kim’s study on the up-regulation of vascular 
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endothelial growth factor (VEGF) expression in oral squamous cell carcinoma, 
immunohistochemical staining with VEGF, found a very little expression of VEGF 
in normal oral squamous cell tissues and a significant positive relationship between 
VEGF expression and the degree of differentiation or invasiveness of carcinoma 
[62]. In addition, histopathological findings showed that the VEGF had higher 
expression levels in less-differentiated invasive oral squamous cell carcinoma, while 
it was expressed at slightly higher levels in well-differentiated and less-invasive 
intraepithelial carcinoma tissues or highly differentiated oral squamous cell carci-
noma than in normal cells [62]. In contrast, Shang and Li found that VEGF expres-
sion was significantly higher in patients in patients with stage 1 and 2 tumors as 
compared to when there were a stage 3 and 4 tumors [63].
4.3 The role of VEGF in prognosis
Interestingly, some studies have focused on the potential prognostic importance 
of VEGF polymorphisms in head and neck cancers [14, 20, 21]. Results showed 
the association between −1154GG VEGF genotype, located in the promoter region 
of the gene, and higher VEGF production [12]. A study conducted by Ku et al., 
reported an association of −460C/T polymorphism and VEGF overexpression in 
oral cancer, showing a higher risk for oral cancer in the patients with a high −460TC 
ratio [66, 67]. Further investigations showed an association between +960C/T 
VEGF polymorphism and oral cancer [23], indicating that the low production of 
VEGF by the T allele is correlated with increased risk of oral cancer, and vascular 
invasion in oral squamous cell carcinoma. In contrast, Vairaktaris et al. [56], did not 
demonstrate an influence of gene polymorphism on the oral cancer in the logistic 
regression models. However, the genotype VEGF −460CT was associated with 
early stage tumors. Nasr et al. analyzed the polymorphism VEGF −2578C/A and 
suggested that carriers of VEGF −2578C allele may play a role in susceptibility to 
nasopharyngeal carcinoma [64, 65]. The risk for laryngeal squamous cell carcinoma 
seems to be linked with the increase of the −1154G/G genotype of the VEGF gene, 
in the −1154G/A polymorphism of the VEGF [27]. Moreover, the polymorphism 
−1154G/A VEGF has been shown to be associated with differential expression of 
VEGF in vitro. However, some of the data are contradictory.
4.4  Vascular endothelial growth factor and advances in developing novel 
therapeutic strategies for oral squamous cell carcinoma
There is a great need for therapies to prevent and/or slow the progression 
of OSCC. Recent studies focused on potential of drugs that target VEGF or its 
receptors-signaling system because their angiogenesis-promoting activity at the 
level of endothelial cells. Therefore, modulation of these factors to inhibit tumor 
angiogenesis, currently, is a major focus in developing OSCC therapies. The devel-
opment of angiogenesis inhibitors as anticancer agents have been developed with 
data showing promising efficacy at reducing OSCC in in vitro models [13, 14]. 
Recent studies found that administration of angiogenesis inhibitors agents in 
association with chemotherapy and radiotherapy can improve the efficacy of these 
treatments. For example, Teicher et al. observed that coadministration of the 
TNR-470, angiogenesis inhibitor agent, induces a substantial cyclophosphamide-
induced tumor cell-killing. Jain’s study confirmed these findings suggesting that it 
was a consequent normalization of the tumor vasculature, as a result of endothelial 
cell death. Different therapeutic strategies to induce the inhibition of VEGF or its 
receptor signaling system are being emerging for treatment of OSCC, as VEGFR-1 
ribozymes, VEGF toxin conjugates, and soluble VEGF receptors.
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5. Conclusions
Angiogenesis is essential for the growth and metastasis of solid tumors, includ-
ing oral squamous cell carcinoma. The main factor responsible for angiogenesis is 
VEGF and its receptors. Specifically, VEGF-A is known to be a key angiogenic factor, 
and its overexpression has been reported in most types of cancer, including oral 
squamous cell carcinoma, and it is thought to be a prognostic factor for survival. It 
was pointed out that VEGF as an attractive candidate for therapeutic intervention, 
but more studies are needed to clarify the real potential of angiogenesis inhibitors 
agents in OSCC, to determine optimal timing for VEGF, and to search for drug 
candidates.
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